V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016780 | 160019218 | 1.63 | null | Curative (C) | 2016-08-18 | 2016-08-18 | GEMCITABINE | 02 | N | IPILIMUMAB + NIVOLUMAB | 100363669 |
| 160016784 | 160019219 | 1.56 | null | Neo-adjuvant (N) | null | null | ETOP 13-18 BEAT-meso Trial | 02 | N | ENZALUTAMIDE | 101548082 |
| 160016796 | 160019220 | 1.67 | 30 | Palliative (P) | 2019-08-22 | 2019-08-23 | EW EuroEwing 2012 Arm A/B Zol Acid | 02 | null | VAI | 101456359 |
| 160016810 | 160019221 | 0 | 84 | Curative (C) | 2018-10-01 | 2018-10-01 | Doxorubicin + Ifosfamide | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101402124 |
| 160016811 | 160019222 | 1.76 | 64.1 | null | null | null | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | RUCAPARIB | 100428216 |
| 160016838 | 160019223 | 1.6 | 15.8 | null | 2016-10-04 | 2016-10-04 | Etoposide oral | null | null | SUNITINIB | 100101467 |
| 160016852 | 160019225 | null | 121.4 | null | 2016-09-17 | 2017-03-25 | Doxorubicin chemoembolisation | 02 | null | VINCRISTINE | 100332645 |
| 160016868 | 160019226 | 1.1 | 56.1 | null | 2020-08-25 | 2020-09-18 | null | 02 | null | IFOSFAMIDE | 101197738 |
| 160016869 | 160019227 | 1.56 | 93.9 | null | 2018-09-12 | 2019-04-05 | Olaratumab | 02 | null | OLAPARIB | 100954955 |
| 160016877 | 160019228 | 1.8 | 49.95 | Palliative (P) | null | 2018-03-12 | Cyclophosphamide oral | 02 | N | VINCRISTINE | 100841815 |
| 160016885 | 160019229 | 1.84 | 75.4 | Palliative (P) | 2020-09-03 | 2020-09-26 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | STS RHABDO VIT0910 VINC IRINO TEMOZ | 101028116 |
| 160016889 | 160019230 | 1.67 | 76.2 | null | 2017-03-07 | 2017-03-28 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100828540 |
| 160016893 | 160019231 | 1.64 | 36.5 | Curative (C) | 2019-02-26 | 2020-11-18 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | CARBOPLATIN + ETOPOSIDE | 100280433 |
| 160016895 | 160019232 | 1.67 | 121 | Curative (C) | 2019-04-16 | 2019-05-16 | Ifosfamide | 02 | Y | CYCLOPHOSPHAMIDE + VINORELBINE | 100586589 |
| 160016921 | 160019234 | 0 | 17.4 | null | null | 2021-08-03 | ATOMIC-MESO TRIAL | null | null | IFOSFAMIDE + VINCRISTINE | 100601969 |
| 160016923 | 160019235 | 1.68 | 17.4 | Palliative (P) | 2016-07-20 | 2016-08-02 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100612536 |
| 160016953 | 160019236 | 1.69 | 75.7 | Palliative (P) | 2015-10-31 | 2016-04-21 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | N | EURO-EWING | 100054016 |
| 160016955 | 160019237 | 0 | 18.3 | null | 2018-12-26 | 2019-03-26 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | null | CAPECITABINE + TEMOZOLOMIDE | 101863220 |
| 160016959 | 160019238 | 1.68 | 95.6 | Palliative (P) | null | 2020-06-01 | ETOPOSIDE | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100659204 |
| 160016965 | 160019239 | 0 | 74 | Palliative (P) | 2017-06-11 | 2018-05-09 | Olaratumab | 02 | null | NOT MATCHED | 100019609 |
| 160016971 | 160019240 | 1.63 | 72.6 | Palliative (P) | 2019-11-25 | 2019-12-08 | FLUOROURACIL + OXALIPLATIN | 02 | N | PAZOPANIB | 100977599 |
| 160016975 | 160019241 | 1.55 | 66.8 | Palliative (P) | 2019-05-14 | 2019-05-14 | CYCLOPHOSPHAMIDE | 02 | N | PEMETREXED | 100761456 |
| 160016986 | 160019242 | 1.84 | 43.15 | Adjuvant (A) | 2018-11-05 | 2018-11-19 | Cyclophosphamide oral | 02 | N | OLAPARIB | 100200365 |
| 160016988 | 160019243 | 1.64 | 29 | null | 2019-03-31 | 2019-04-02 | null | 02 | null | EW EUROEWING 2012 ARM B IE | 100910350 |
| 160016990 | 160019244 | 1.79 | 63.7 | Palliative (P) | null | 2021-12-21 | CYCLOPHOSPHAMIDE + VINORELBINE | N | null | ETOPOSIDE + IFOSFAMIDE | 101822042 |
| 160016993 | 160019245 | 1.67 | 9.6 | Adjuvant (A) | 2017-10-22 | 2017-11-12 | Bevacizumab+Carbo+Pacliaxel | 01 | N | TAZEMETOSTAT | 100212183 |
| 160016996 | 160019246 | null | 63 | null | 2021-08-09 | 2021-09-09 | Niraparib | 02 | null | OLARATUMAB | 100086284 |
| 160017000 | 160019247 | 1.7 | 16.3 | null | 2017-08-02 | 2018-03-26 | EW EuroEwing 2012 Arm B VC | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 101514865 |
| 160017009 | 160019248 | 1.64 | 24.6 | null | 2019-08-12 | 2019-08-12 | VCDE RMS | 02 | null | ETOPOSIDE + IFOSFAMIDE | 101316985 |
| 160017011 | 160019249 | 1.8 | 10.8 | Curative (C) | 2018-10-27 | 2018-10-28 | Cisplatin + Etoposide (3 day) | 02 | N | MELPHALAN + TREOSULPHAN | 100970885 |
| 160017014 | 160019250 | 1.62 | 0 | Curative (C) | 2016-01-07 | 2016-05-19 | Ifosfamide | 1 | Y | PROMISE-MESO TRIAL | 101467040 |
| 160017019 | 160019251 | 1.65 | 92.9 | null | 2018-03-08 | 2018-03-28 | Trial Unspecified | 02 | null | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 100745063 |
| 160017024 | 160019252 | 1.69 | 55.1 | null | null | 2017-09-04 | GEMCITABINE | 02 | N | RUCAPARIB | 101513533 |
| 160017030 | 160019253 | 1.73 | 49.6 | null | 2017-01-29 | 2017-11-04 | Cyclophosphamide oral | 02 | null | CONFIRM TRIAL | 101823003 |
| 160017032 | 160019254 | 1.62 | 59.6 | Curative (C) | 2021-06-28 | 2021-06-28 | EW Rel rEECur Irinotecan/Temozolomide | Y | N | CONFIRM TRIAL | 101275146 |
| 160017044 | 160019255 | 1.83 | 14.2 | Curative (C) | 2017-09-24 | 2018-01-21 | CONFIRM TRIAL | 02 | N | CONFIRM TRIAL | 101125629 |
| 160017045 | 160019256 | 1.71 | 64 | Palliative (P) | null | 2019-11-28 | STS Rhabdomyosarcoma RMS 2005 IVA | Y | N | EW EUROEWING 2012 ARM A VAI | 100263234 |
| 160017052 | 160019257 | 0 | 63.25 | Palliative (P) | 2018-04-06 | 2018-04-14 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100940818 |
| 160017054 | 160019258 | null | null | Palliative (P) | 2020-12-15 | 2021-12-24 | R CODOX-M/ R IVAC | 01 | N | CYCLOPHOSPHAMIDE | 101068411 |
| 160017067 | 160019259 | 1.53 | 46.5 | Adjuvant (A) | 2020-12-16 | 2020-12-30 | Dacarbazine | 01 | N | TRIAL | 100157495 |
| 160017076 | 160019260 | 1.95 | 93.1 | Curative (C) | 2019-11-07 | 2019-11-07 | Irinotecan + Temozolomide | 01 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101525979 |
| 160017106 | 160019261 | 1.69 | 91.9 | Palliative (P) | 2020-09-03 | 2021-09-26 | STS Rhabdo VIT0910 Vinc Irinotecan | 01 | N | PEMBROLIZUMAB | 100451101 |
| 160017119 | 160019262 | 1.82 | 80 | Curative (C) | 2020-06-12 | 2020-06-18 | Trial Unspecified | 02 | N | EW EUROEWING 2012 ARM A VIDE | 100674859 |
| 160017127 | 160019263 | 1.88 | 79.6 | null | 2021-12-04 | 2021-12-09 | Cyclophosphamide oral | 02 | null | EW EUROEWING 2012 ARM B VDC | 101584547 |
| 160017128 | 160019264 | 1.93 | 89.9 | Curative (C) | 2017-03-28 | 2017-03-31 | STS Rhabdomyosarcoma RMS 2005 IVA | N | Y | STS RHABDO RMS 2005 VIN CYCLO | 100315424 |
| 160017140 | 160019265 | 1.64 | 104 | Curative (C) | 2020-10-07 | 2020-11-16 | null | 02 | null | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100022048 |
| 160017158 | 160019267 | 0 | 88.7 | null | 2018-04-26 | 2018-12-02 | EW Rel rEECur Topotecan/Cyclophosphamide | 02 | null | IVA | 101600360 |
| 160017159 | 160019268 | 1.58 | 67.6 | Curative (C) | 2020-10-14 | 2020-10-23 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | ETOPOSIDE + IFOSFAMIDE | 101794810 |
| 160017162 | 160019269 | 1.77 | 12.7 | null | 2020-04-10 | 2020-12-28 | Rituximab | 02 | null | ACALABRUTINIB | 100936393 |
| 160017164 | 160019270 | 1.67 | null | Curative (C) | 2020-06-12 | 2020-07-17 | null | 01 | N | IVA | 100139910 |